FdaApplication
NDA 211996
Identifiers
- fda_app_no: NDA211996
Properties
| Property | Value |
|---|---|
| applicant_name | FOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC |
| application_type | NDA |
| approval_date | 2019-05-03 |
Revenue by product
VYNDAQEL
| Period | Revenue |
|---|---|
| Q2 2026 | $1.8B |
| Q1 2026 | $1.6B |
| Q3 2025 | $1.6B |
| Q2 2025 | $1.6B |
| Q1 2025 | $1.5B |
| Q3 2024 | $1.4B |
| Q2 2024 | $1.3B |
| Q1 2024 | $1.1B |
| Q4 2023 | $961.0M |
| Q3 2023 | $892.0M |
| Q2 2023 | $782.0M |
| Q1 2023 | $686.0M |
| Q4 2022 | $681.0M |
| Q3 2022 | $602.0M |
| Q2 2022 | $552.0M |
| Q1 2022 | $612.0M |
| Q4 2021 | $561.0M |
| Q3 2021 | $501.0M |
| Q2 2021 | $501.0M |
| Q1 2021 | $453.0M |
| Q4 2020 | $429.0M |
| Q3 2020 | $351.0M |
| Q2 2020 | $277.0M |
| Q1 2020 | $231.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VYNDAQEL | TAFAMIDIS MEGLUMINE | 20MG | CAPSULE;ORAL |
1 product